Patient characteristics
| Variable . | Group . | Overall, N = 313 . | European, N = 214 . | Non-European, N = 99 . | P value . |
|---|---|---|---|---|---|
| Age, y | Median age (range) | 56 (19-70) | 60 (22-70) | 49 (19-69) | <.001∗ |
| ≤56, n (%) | 160 (51) | 92 (43) | 68 (69) | ||
| >56 y, n (%) | 153 (49) | 122 (57) | 31 (31) | ||
| Sex, n (%) | Male | 163 (52) | 118 (55) | 45 (45) | .11 |
| Female | 150 (48) | 96 (45) | 54 (55) | ||
| 2017 ELN criteria13, n (%) | Favorable/intermediate | 228 (73) | 157 (73) | 71 (72) | .76 |
| Adverse | 85 (27) | 57 (27) | 28 (28) | ||
| HCT-CI | Median score (range) | 2 (0-11) | 2 (0-8) | 3 (0-11) | .028∗ |
| 0-2, n (%) | 183 (58) | 134 (63) | 49 (49) | ||
| 3+, n (%) | 130 (42) | 80 (37) | 50 (51) | ||
| AML induction regimen, n (%) | Cytarabine & anthracycline | 243 (78) | 161 (75) | 82 (83) | .37 |
| Liposomal daunorubicin & cytarabine | 24 (8) | 17 (8) | 7 (7) | ||
| Venetoclax & azacytidine | 14 (4) | 12 (6) | 2 (2) | ||
| Other | 32 (10) | 24 (11) | 8 (8) | ||
| Referral type, n (%) | Internal | 199 (64) | 139 (65) | 60 (61) | .5 |
| External | 114 (36) | 75 (35) | 39 (39) | ||
| Graft source†, n (%) | HLA-identical sibling | 67 (21) | 45 (21) | 22 (22) | <.001∗ |
| 8/8 URD | 149 (48) | 117 (55) | 32 (32) | ||
| CB | 69 (22) | 36 (17) | 33 (33) | ||
| Haploidentical | 17 (5) | 8 (3.5) | 9 (9) | ||
| mmURD | 11 (4) | 8 (3.5) | 3 (3) | ||
| Period, n (%) | Prepandemic | 260 (83) | 176 (82) | 84 (85) | .6 |
| Pandemic | 53 (17) | 38 (18) | 15 (15) |
| Variable . | Group . | Overall, N = 313 . | European, N = 214 . | Non-European, N = 99 . | P value . |
|---|---|---|---|---|---|
| Age, y | Median age (range) | 56 (19-70) | 60 (22-70) | 49 (19-69) | <.001∗ |
| ≤56, n (%) | 160 (51) | 92 (43) | 68 (69) | ||
| >56 y, n (%) | 153 (49) | 122 (57) | 31 (31) | ||
| Sex, n (%) | Male | 163 (52) | 118 (55) | 45 (45) | .11 |
| Female | 150 (48) | 96 (45) | 54 (55) | ||
| 2017 ELN criteria13, n (%) | Favorable/intermediate | 228 (73) | 157 (73) | 71 (72) | .76 |
| Adverse | 85 (27) | 57 (27) | 28 (28) | ||
| HCT-CI | Median score (range) | 2 (0-11) | 2 (0-8) | 3 (0-11) | .028∗ |
| 0-2, n (%) | 183 (58) | 134 (63) | 49 (49) | ||
| 3+, n (%) | 130 (42) | 80 (37) | 50 (51) | ||
| AML induction regimen, n (%) | Cytarabine & anthracycline | 243 (78) | 161 (75) | 82 (83) | .37 |
| Liposomal daunorubicin & cytarabine | 24 (8) | 17 (8) | 7 (7) | ||
| Venetoclax & azacytidine | 14 (4) | 12 (6) | 2 (2) | ||
| Other | 32 (10) | 24 (11) | 8 (8) | ||
| Referral type, n (%) | Internal | 199 (64) | 139 (65) | 60 (61) | .5 |
| External | 114 (36) | 75 (35) | 39 (39) | ||
| Graft source†, n (%) | HLA-identical sibling | 67 (21) | 45 (21) | 22 (22) | <.001∗ |
| 8/8 URD | 149 (48) | 117 (55) | 32 (32) | ||
| CB | 69 (22) | 36 (17) | 33 (33) | ||
| Haploidentical | 17 (5) | 8 (3.5) | 9 (9) | ||
| mmURD | 11 (4) | 8 (3.5) | 3 (3) | ||
| Period, n (%) | Prepandemic | 260 (83) | 176 (82) | 84 (85) | .6 |
| Pandemic | 53 (17) | 38 (18) | 15 (15) |